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There is increasing awareness that multiple, often over-
lapping mechanisms exist for amplifying the repertoire
of protein products specified through the mammalian
genome. An expanding array of processing and target-
ing mechanisms is now emerging, each representing a
potentially important restriction point in the regula-
tion of eukaryotic gene expression, and each expanding
the possibilities specified by the literal code of the
genome. These co- and posttranscriptional regulatory
events include capping, alternative splicing, differential
polyadenylation, RNA editing, nuclear export, alterna-
tive decay and degradation pathways, as well as alter-
ations in ribosomal loading or translation. Recent
advances suggest important links between RNA edit-
ing, particularly C→U editing, and other co- and post-
transcriptional events regulating gene expression.
Forms of RNA editing in mammalian cells
In RNA editing, the coding sequence of the transcript is
altered from its genomically templated version. In mam-
mals, two major types of RNA base-modification have
been described, both forms of substitutional editing, in
which a single nucleotide is altered posttranscriptional-
ly (reviewed in ref. 1). These include adenosine-to-inosine
(A→I) and cytidine-to-uridine (C→U) editing. In all
instances where the translation products have been char-
acterized, the product of the edited mRNA acquires
functional characteristics distinct from those of the
product of the unedited transcript (reviewed in ref. 1).
Mammalian A→I RNA editing occurs on an unspliced
mRNA template and requires partial base pairing
between exonic and adjacent intronic sequences in a dou-
ble-stranded RNA conformation. Inosine is translated as
guanosine in the edited mRNA, so the effect of editing
mimics that of an A→G change. Examples of transcripts
that undergo A→I editing include the calcium-gated glu-
tamate receptor, GluR-B, as well as subtypes of the 5HT2c
receptor and hepatitis δ virus (1). A family of adenosine
deaminases acting on RNA (ADARs) is responsible for
these A→I editing events, all of which operate through
hydrolytic deamination of a defined target transcript (2).
Members of the ADAR family function as modular
enzymes and operate in vitro without obligate cofactor
requirements. Each ADAR contains a C-terminal deami-
nase domain and an N-terminal domain with varying
numbers (two or three) of double-stranded RNA-binding
motifs (1, 3). These features of A→I RNA editing, name-
ly the cis-acting requirements, the range of targets, and
the enzymatic machinery, serve as useful reference points
in understanding the mechanisms regulating the second
form of base-modification editing, C→U RNA editing.
C→U RNA editing involves a site-specific deamina-
tion of cytidine in a nuclear transcript that is mediated
by an enzyme complex. Physiological targets for mam-
malian C→U editing are currently confined to nuclear
mRNAs encoding apoB and neurofibromatosis type I
(NF1) transcripts. C→U RNA editing is mediated by an
enzyme complex for which some but not all the com-
ponent factors are known and which, unlike A→I edit-
ing, requires a minimum of two protein components
acting on a suitable template to reproduce targeted
enzymatic deamination in vitro.
Cis-acting requirements
The original and most fully detailed example of C→U
RNA editing is mammalian apoB mRNA, in which a
site-specific cytidine deamination introduces a UAA
stop codon into the translational reading frame, result-
ing in synthesis of a truncated protein, apoB48
(reviewed in ref. 4). C→U RNA editing of apoB occurs
within enterocytes of the mammalian small intestine, as
well as in the liver in some species (reviewed in ref. 4).
Under physiological circumstances, C→U editing of
apoB mRNA targets a single cytidine out of more than
14,000 nucleotides, a process constrained by stringency
in the cis-acting elements and by the protein factors
responsible for targeted deamination. These cis-acting
elements, which have been well described in recent
reviews (1, 4), include an AU-rich bulk RNA context in
which an 11-nucleotide motif occurs four nucleotides
downstream of the targeted cytidine. This sequence is
flanked by elements both 5′ and 3′ of a minimal,
approximately 50-nucleotide editing cassette. Structur-
al predictions indicate that this region assumes signifi-
cant secondary structure (5–8) with the targeted cyti-
dine exposed at the apex of a stem-loop bulge. The most
plausible interpretation of these collective requirements
is to coordinate optimal alignment of the substrate with
respect to the active site of the editing enzyme.
RNA splicing precedes C→U RNA editing and helps
account for the specificity of the latter processing event.
ApoB RNA editing occurs within the nucleus, and its
preferred substrate is spliced, polyadenylated RNA. The
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relationship between RNA splicing and C→U editing
has been explored directly in recent studies by Smith
and colleagues, who demonstrated that chimeric apoB
RNA substrates containing an intron either 5′ or 3′ to
the minimal editing cassette are edited in cultured cells
with lower efficiency than a spliced template of other-
wise identical sequence (9, 10). These authors also
explored effects of conditional export of an unspliced
apoB RNA chimera in which an editing cassette had
been inserted within an intron, upstream of a Rev
response element (RRE). Cells cotransfected with this
chimeric plasmid and with a Rev expression construct
that allowed for nuclear export of the unspliced tran-
script as a result of Rev-RRE binding (10). Under these
conditions, the unspliced apoB RNA chimera was effi-
ciently edited, suggesting but not formally proving that
editing takes place in the nucleus (10). These findings
indicate that targeting of pre-mRNA to the splicing
pathway may be inhibitory to C→U RNA editing, and
they suggest that pre-mRNA is not the preferred sub-
strate. Hence, C→U editing apparently follows RNA
splicing. In this respect, it differs from A→I, which
appears to be tightly coupled to splicing (11).
It remains to be determined whether the binding of
splicing factors in proximity to the splice donor and
acceptor sites of pre-mRNA inhibits the binding or other
regulatory functions of the proteins involved in C→U
editing. This question is of importance since apoB RNA
editing occurs in the middle of a large exon (>7 kb), the
targeted cytidine being flanked by >2 kb of exonic
sequence, presumably a site remote from the region to
which the splicing machinery attaches.
RNA splicing plays a distinct but no less central role in
the C→U editing of NF1. Earlier descriptions of NF1
RNA editing indicated that a subset of tumors manifest-
ed C→U RNA editing, changing an arginine CGA to a
UGA termination codon (12). Two distinguishing fea-
tures of tumors that edit the NF1 RNA have emerged.
First, they produce an alternatively spliced NF1 RNA in
which an exon downstream of the edited base is includ-
ed. Second, they express the mRNA for apobec-1, the cat-
alytic deaminase of the apoB RNA editing enzyme (13).
The presence of the alternatively spliced exon (23A) in
NF1 transcripts that undergo C→U editing is predicted
through molecular modeling (D. Mukhophadyay et al.,
unpublished observations) to position the targeted cyti-
dine in a favorable configuration relative to apobec-1.
Thus, important functional interactions between local
and distant cis-acting elements, in conjunction with the
regulated expression of trans-acting factors, together
modulate C→U editing activity and specificity. The func-
tional and clinical significance of C→U editing of NF1
RNA in these tumors is not resolved, but the findings
suggest a new level of genetic heterogeneity in relation to
the loss of tumor suppressor function of neurofibromin.
Trans-acting factors
C→U RNA editing is mediated by an enzyme complex
that includes the RNA-specific cytidine deaminase
apobec-1 (4) and apobec-1 complementation factor
(ACF), a novel protein that likely serves as the RNA recog-
nition component of the core enzyme complex (14, 15).
RNA-specific cytidine deaminases. Apobec-1, the catalytic
subunit of the apoB RNA–editing holoenzyme, is a
developmentally regulated RNA-specific cytidine deam-
inase expressed almost exclusively in the luminal gas-
trointestinal tract of humans (reviewed in ref. 4). The
recent finding that apobec-1 mRNA occurs in a subset
of tumors in patients with neurofibromatosis provides
the first example of its expression beyond the gastroin-
testinal tract in humans (13). The expression and local-
ization pattern of apobec-1 in the human small intestine
coincides with that of its presumed target, apoB mRNA,
but apobec-1 expression in peripheral tissues of rodents,
including sites that express virtually no apoB mRNA,
remains enigmatic. The targeted deletion of the murine
apobec-1 confirmed that this protein is required for C→U
RNA editing of apoB and for production of plasma
apoB48 but yielded no obvious clues to an auxiliary or
covert function for apobec-1 (reviewed in refs. 1, 4).
Homologs of apobec-1 have been identified in both
human and murine databases, and two such homologs,
activation induced deaminase (AID) and apobec-
2/ARCD-1, have recently been characterized in detail.
AID was identified in a genetic screen of differentially
expressed products detected during lymphocyte activa-
tion and Ig class switch recombination. Targeted dis-
ruption of AID in mice leads to elevated levels of serum
IgM concentration and defective class switch recombi-
nation, as well as alterations in somatic hypermutation
(16). AID exhibits cytidine deaminase activity on a
monomeric substrate, but no authentic RNA target has
yet emerged for its activity in vivo, and its cofactor
requirements are unknown. Its chromosomal location,
close to that of APOBEC1 on 12p13, suggests that it may
have arisen as a gene duplication. Another homolog of
apobec-1 has been identified that also manifests cytidine
deaminase activity on a monomeric substrate. This
homolog, the product of a locus on chromosome 6p21,
referred to as apobec-2 (17) or apobec-1–related cytidine
deaminase 1 (ARCD-1) (18), has no C→U editing activi-
ty on apoB RNA (hence its designation as a related deam-
inase) but rather inhibits apobec-1–mediated RNA edit-
ing through its ability to interact with apobec-1 and with
ACF (18). The inhibition of apobec-1–mediated C→U
RNA editing by ARCD-1 is reminiscent of the inhibition
of ADAR1- and ADAR2a-mediated A→I editing of
5HT2c receptor RNAs by a related homolog, ADAR3 (3).
These findings considered together raise the possibility
that some members of the gene family of RNA-specific
deaminases play a tissue-specific regulatory role in mod-
ulating target specificity and enzyme activity, perhaps
through interactions with other members.
The RNA-binding subunit. Using independent affinity
enrichment strategies, two groups simultaneously
identified a second component of the apoB RNA–edit-
ing holoenzyme (14, 15) that, together with apobec-1,
is both necessary and sufficient to mediate C→U RNA
editing in vitro. This novel 65-kDa protein, ACF (14) or
apobec-1–stimulating protein (15), represents the reg-
ulatory subunit of the core enzyme; recombinant
apobec-1 and ACF are sufficient to recapitulate effi-
cient editing of a synthetic apoB RNA template in vitro
(14, 15, 19). ACF mRNA is developmentally regulated
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and ubiquitously expressed in normal human tissues
(albeit at low levels) and is detectable in tumors from
NF1 patients (13–15, 20). Apobec-1 and ACF together
represent the minimal core of the holoenzyme,
although their physiological stoichiometry within the
native holoenzyme is not fully understood. Apobec-1,
for instance, functions as a homodimer of about 27
kDa monomers and, along with ACF, constitutes the
core of a holoenzyme complex that sediments at 27S
and likely includes numerous other proteins (21, 22).
ACF contains three nonidentical RNA recognition
motifs as well as a carboxyl-terminus arginine-
glycine–rich region and a double-stranded RNA-bind-
ing domain (14, 15). The presence of these various RNA-
binding motifs led to predictions, experimentally
confirmed (14, 15, 19), that ACF would bind apoB RNA
with high specificity. Recent studies have defined more
precisely the functional domains of ACF and have
revealed that the amino-terminal 380 residues of ACF
contain the apoB RNA–binding domains as well as the
domain responsible for physical interaction with
apobec-1 (23). These domains overlap in a region span-
ning the second and third RNA recognition motif (23).
The carboxyl-terminus arginine-glycine–rich domain,
and also the double-stranded RNA-binding domain,
each appear dispensable for C→U editing complemen-
tation (23), and more recent studies suggest that virtu-
ally complete in vitro complementation activity is
retained in the amino-terminal 380 residues of ACF (V.
Blanc et al., unpublished observations).
Formation of the C→U editing complex
The data from in vitro, reconstituted systems indicate
that ACF and apobec-1 interact physically with each
other and with a synthetic apoB RNA template to coor-
dinate C→U editing (14, 15, 19, 24) within the nucleus.
Both ACF and apobec-1 are low-abundance proteins
and localization of their endogenous products
has proven challenging, but ACF has indeed been
localized to the nucleus in transfected cells and,
upon cotransfection with apobec-1, results in
nuclear colocalization and redistribution of
apobec-1 from a predominantly cytoplasmic
location (19, 23, 24). These findings suggest that
apobec-1 translocates into the nucleus, in associ-
ation with ACF, raising the possibility of a shut-
tling function for one or both proteins.
Other proteins also interact with apobec-1 and/or apoB
RNA. For instance, we and others have identified a
homolog of ACF, GRY-RBP, within an S100 fraction of
intestinal extracts that is enriched for C→U RNA editing
activity (19, 25). GRY-RBP contains homologous RNA-
binding domains to ACF, binds short apoB RNA tem-
plates, and also binds and colocalizes with both apobec-
1 and ACF (19). Unlike ACF, GRY-RBP exhibits no C→U
RNA editing complementation activity (19). Several other
proteins, identified through two-hybrid or other genetic
screens, have been demonstrated to interact with apobec-
1 and to bind apoB RNA; many of these exhibit modula-
tory activity. Indeed, the original descriptions of apoB
RNA–editing activity within 27S particles isolated from
rat liver strongly implied the presence of a large multi-
component complex (21). One such protein, CUGBP2,
cofractionates in a complex enriched in C→U RNA-edit-
ing complementation activity and binds apoB RNA, colo-
calizing in the nucleus with apobec-1 and ACF (22). Like
GRY-RBP, CUGBP2 inhibits C→U RNA editing of apoB,
most plausibly by forming a regulatory complex with
each of the essential components of the core enzyme
complex, apobec-1, ACF, and apoB RNA (22).
It bears emphasis that apobec-1 itself binds apoB RNA,
albeit with low affinity, and conservative mutations
within apobec-1 that eliminate its RNA binding without
compromising its cytidine deaminase activity abrogate
C→U RNA editing of apoB (26, 27). Thus, the RNA-
binding activity of apobec-1 may in itself constrain tar-
get specificity. Accordingly, a considerable focus of
research activity is directed toward identifying trans-act-
ing components whose presence within the apoB
RNA–editing holoenzyme may regulate target RNA
binding and restrict cytidine deamination of other tran-
scripts. Remarkably, forced overexpression of apobec-1
in the livers of transgenic mice and rabbits is associated
with promiscuous RNA editing of multiple cytidines,
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Figure 1
Posttranscriptional C→U RNA editing. Following transcription,
nascent pre-RNA associates with hnRNPs and splicing factors.
Spliced mRNA is shown with the minimal core complex of the
apoB RNA holoenzyme (apobec-1 plus ACF) in proximity to the
targeted cytidine. Note that apobec-1 functions as a dimer and
that the stoichiometry of binding (ACF/apobec-1) is currently
unknown. The activity of the core enzyme complex is regulated
through protein-protein interaction of both apobec-1 and ACF,
each with a number of proteins that may together represent the
larger holoenzyme complex. ACF is proposed to function in the
translocation of apobec-1, as well, and is illustrated here shuttling
between the nucleus and cytoplasm.
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beyond the canonical site in apoB RNA, and leads to
hepatic dysplasia and hepatocellular carcinoma (28, 29).
A final consideration is the extent to which protein
components of the RNA-editing machinery may partici-
pate in other aspects of RNA processing. One component
with such overlapping functions is KSRP, an approxi-
mately 75-kDa KH-type splicing regulatory protein.
KSRP binds to a cluster of intronic regulatory elements
downstream of exon N1 of c-src and participates in the
assembly of a heterogenous nuclear ribonuclear binding
protein (hnRNP) complex that regulates alternative splic-
ing in neural tissues (30). In a rat liver nuclear extract
highly enriched in C→U editing activity, KSRP copurifies
with ACF (15). KSRP also demonstrates high-affinity
apoB RNA binding (15). Its role in C→U RNA editing
awaits further study, but even independent of its role in
RNA splicing and C→U RNA editing, KSRP was recent-
ly identified as a component of the mammalian exosome,
a complex of exonucleases believed to regulate the
turnover of short-lived, AU-containing mRNA species
(31). The cumulative evidence thus points to a wide range
of potential targets for KSRP and suggests that compo-
nents of one macromolecular complex might participate
in other higher-order complexes that act on newly syn-
thesized mRNAs. In this regard, it is interesting to note
that a number of hnRNPs have also been identified as
apobec-1–interacting proteins, although their role in
modulating nuclear mRNA metabolism in general and
C→U RNA editing in particular is unresolved (Figure 1).
The emerging information points to a growing complex-
ity in the composition, regulation, and function of the
C→U RNA-editing machinery. The ability of these vari-
ous constituents to associate interchangeably with dif-
ferent multicomponent complexes within the nucleus
and to discriminate target RNAs through subtle alter-
ations in their secondary and tertiary structures implies
that other functions will emerge through selective genet-
ic manipulation in selected model systems.
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